Abstract
Previously, studies of the endocrine pancreatic β-cell were mainly performed ex vivo by morphological means. This data supported the analyis of pathophysiological changes in the pancreatic islet during insults such as diabetes mellitus. Metabolic testing of the pancreatic islet by assaying hormone parameters such as plasma insulin or C-peptide combined with more or less sophisticated calculations allowed conclusions about states of insulin resistance or secretory failure. It also allowed certain correlations of endocrine function with β-cell mass. Today, with firmer pathophysiological concepts about β-cell failure, modern protocols of islet transplantation, and drugs on the market coming with promises of preservation or even expansion of β-cell mass in diabetes mellitus it has become very attractive to search for tools measuring β-cell mass, if possible even repeatedly in the same organism in vivo. From a clinical point of view, the potential of pancreatic β-cell mass imaging technologies is looked upon with high expectations. Methodologically, the decisive question is whether it is likely that future β-cell imaging will provide significant advantages over the metabolic methods already in hand. With new in vivo tools, studies of β-cell mass and function may offer even new approaches stratifying patients to anti-diabetic therapies.
Keywords: diabetes mellitus, C-peptide, OGTT, pancreatic β-cell
Current Pharmaceutical Design
Title: What are the Potential Benefits of Clinical β-Cell Imaging in Diabetes Mellitus?
Volume: 16 Issue: 14
Author(s): Burkhard Goke
Affiliation:
Keywords: diabetes mellitus, C-peptide, OGTT, pancreatic β-cell
Abstract: Previously, studies of the endocrine pancreatic β-cell were mainly performed ex vivo by morphological means. This data supported the analyis of pathophysiological changes in the pancreatic islet during insults such as diabetes mellitus. Metabolic testing of the pancreatic islet by assaying hormone parameters such as plasma insulin or C-peptide combined with more or less sophisticated calculations allowed conclusions about states of insulin resistance or secretory failure. It also allowed certain correlations of endocrine function with β-cell mass. Today, with firmer pathophysiological concepts about β-cell failure, modern protocols of islet transplantation, and drugs on the market coming with promises of preservation or even expansion of β-cell mass in diabetes mellitus it has become very attractive to search for tools measuring β-cell mass, if possible even repeatedly in the same organism in vivo. From a clinical point of view, the potential of pancreatic β-cell mass imaging technologies is looked upon with high expectations. Methodologically, the decisive question is whether it is likely that future β-cell imaging will provide significant advantages over the metabolic methods already in hand. With new in vivo tools, studies of β-cell mass and function may offer even new approaches stratifying patients to anti-diabetic therapies.
Export Options
About this article
Cite this article as:
Goke Burkhard, What are the Potential Benefits of Clinical β-Cell Imaging in Diabetes Mellitus?, Current Pharmaceutical Design 2010; 16 (14) . https://dx.doi.org/10.2174/138161210791164081
DOI https://dx.doi.org/10.2174/138161210791164081 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
In Vitro Infection of Human Monocyte-Derived Dendritic Cells with Candida albicans: Receptorial Involvement and Therapeutic Implications
Current Pharmaceutical Design Associations between Periodontitis and Systemic Inflammatory Diseases: Response to Treatment
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery N-Acetylcysteine for the Treatment of Obsessive-Compulsive Disorder
Current Psychiatry Reviews Renoprotective Effects of SGLT2 Inhibitors: Beyond Glucose Reabsorption Inhibition
Current Vascular Pharmacology Mitochondria Associated Membranes (MAMs): Emerging Drug Targets for Diabetes
Current Medicinal Chemistry Pathogenicity of the 1918 Pandemic Influenza Virus
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Selective Glucocorticoid Receptor Ligands
Medicinal Chemistry N-Aroylated Isatins: Antiglycation Activity
Letters in Drug Design & Discovery Obstructive Sleep Apnoea Syndrome and Diabetes. Fortuitous Association or Interaction?
Current Diabetes Reviews Specificities of the Diabetic Population in French Guiana: The Health Barometer Survey
Current Diabetes Reviews subject Index To Volume 3
Current Protein & Peptide Science Microcirculation of the Diabetic Foot
Current Pharmaceutical Design Editorial: Look for Changes in 2016
Current Molecular Medicine The Atherogenic Dyslipidemia of Metabolic Syndrome- Are there New Effective Therapeutic Options Beyond Statins?
Current Drug Therapy Platelet Hyperreactivity and Stent Thrombosis in Patients Undergoing Coronary Stenting
Current Vascular Pharmacology Potential Therapeutic Properties of Natural Products Through the Expression of Heme Oxygenase-1
Mini-Reviews in Organic Chemistry Editorial (Thematic Issue: Current Topics in Pharmacogenomics)
Recent Patents on Biotechnology Does Metformin Satisfy as an Option for Host-Directed Therapy in COVID-19?
Anti-Infective Agents Supplementation, Optimal Status, and Analytical Determination of Vitamin D: Where are we Standing in 2012?
Anti-Cancer Agents in Medicinal Chemistry Cross-Talk Between Adipose Tissue Health, Myocardial Metabolism and Vascular Function: The Adipose-Myocardial and Adipose-Vascular Axes
Current Pharmaceutical Design